It looks like the key executives in this company make a total of under $10 Million in cash compensation.
I wonder whether the company is "too profitable?" Should they be allowed to make $650 Million? Clearly, cost to manufacture the drug is low at maybe 8% of the selling price. With over 2200 employees they must have something to do, and they spent a half billion in R&D in 2014, or 23% of revenue in R&D.
These are the things YAHOO says they have going on in the R&D area.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders.
So, my question is, ARE THEY MAKING TOO MUCH?
 |  | | |
| Balance Sheet | Get Balance Sheet for: |
| | Period Ending | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | | | Assets | | Current Assets | | Cash And Cash Equivalents | 943,999 | 529,857 | 989,501 | | Short Term Investments | 1,017,567 | 984,994 | - | | Net Receivables | 468,621 | 463,184 | 321,684 | | Inventory | 176,441 | 102,602 | 94,521 | | Other Current Assets | 189,401 | 106,220 | 89,894 | | | Total Current Assets | 2,796,029 | 2,186,857 | 1,495,600 | | Long Term Investments | - | - | - | | Property Plant and Equipment | 392,248 | 201,109 | 165,629 | | Goodwill | 254,073 | 254,073 | 253,645 | | Intangible Assets | 587,046 | 609,719 | 646,678 | | Accumulated Amortization | - | - | - | | Other Assets | 137,627 | 62,544 | 38,054 | | Deferred Long Term Asset Charges | 34,939 | 3,394 | 13,954 | | | Total Assets | 4,201,962 | 3,317,696 | 2,613,560 | | | Liabilities | | Current Liabilities | | Accounts Payable | 439,248 | 423,940 | 271,275 | | Short/Current Long Term Debt | 48,000 | 48,000 | 48,000 | | Other Current Liabilities | 119,492 | 110,489 | 40,814 | | | Total Current Liabilities | 606,740 | 582,429 | 360,089 | | Long Term Debt | 116,599 | 97,230 | 101,000 | | Other Liabilities | 169,559 | 154,717 | 161,794 | | Deferred Long Term Liability Charges | 7,046 | 101,241 | 19,827 | | Minority Interest | - | - | - | | Negative Goodwill | - | - | - | | | Total Liabilities | 899,944 | 935,617 | 642,710 | | | Stockholders' Equity | | Misc Stocks Options Warrants | - | - | - | | Redeemable Preferred Stock | - | - | - | | Preferred Stock | - | - | - | | Common Stock | 20 | 20 | 20 | | Retained Earnings | 1,036,010 | 379,098 | 126,203 | | Treasury Stock | (382,964) | (80,365) | (14,229) | | Capital Surplus | 2,592,167 | 2,106,183 | 1,852,221 | | Other Stockholder Equity | 56,785 | (22,857) | 6,635 | | | Total Stockholder Equity | 3,302,018 | 2,382,079 | 1,970,850 | | | Net Tangible Assets | 2,460,899 | 1,518,287 | 1,070,527 |
|
|
| Income Statement | Get Income Statement for: |
| | Period Ending | Dec 31, 2014Dec 31, 2013Dec 31, 2012 | Total Revenue | 2,233,733 | 1,551,346 | 1,134,114 | | Cost of Revenue | 173,862 | 177,556 | 72,837 | | | Gross Profit | 2,059,871 | 1,373,790 | 1,061,277 | | | Operating Expenses | | Research Development | 513,782 | 317,093 | 222,732 | | Selling General and Administrative | 630,209 | 489,720 | 384,678 | | Non Recurring | 47,174 | 38,550 | 49,112 | | Others | - | 417 | 417 | | | | Total Operating Expenses | - | 845,780 | 656,939 | | | | Operating Income or Loss | 868,706 | 528,010 | 404,338 | | | Income from Continuing Operations | | Total Other Income/Expenses Net | 6,383 | 2,371 | 630 | | Earnings Before Interest And Taxes | 875,089 | 530,381 | 404,968 | | Interest Expense | 2,982 | 4,112 | 7,402 | | Income Before Tax | 872,107 | 526,269 | 397,566 | | Income Tax Expense | 215,195 | 273,374 | 142,744 | | Minority Interest | - | - | - | | | | Net Income From Continuing Ops | 656,912 | 252,895 | 254,822 | | | Non-recurring Events | | Discontinued Operations | - | - | - | | Extraordinary Items | - | - | - | | Effect Of Accounting Changes | - | - | - | | Other Items | - | - | - | | | | Net Income | 656,912 | 252,895 | 254,822 | | Preferred Stock And Other Adjustments | - | - | - | | | Net Income Applicable To Common Shares | 656,912 | 252,895 | 254,822 |
|
|
|
